Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy - 14 day. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy - 14 day, 2023, version number 6a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/447.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC). | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Oxaliplatin, Panitumumab |